This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Conn, P. M. Search for Related Content PubMed Articles by Conn, P. M.

Introduction

Abstract

Introduction: IT IS a novel undertaking that Endocrine Reviews should devote an entire issue to a single subject area. In committing to this project, the Editor-in-Chief and Editorial Board have recognized both the rapid advances made in this area and the potential of GnRH and its analogs to benefit mankind. To date, thousands of GnRH analogs have been synthesized—perhaps more than for any other peptide. Virtually all areas of medicine are being affected by this peptide. The broad interest in GnRH explains why the authors in this volume come from government, industry, and University sources.

Several drug companies now market GnRH and its analogs. In April 1985, the first GnRH analog [Leuprolide, D-Leu⁶-Pro⁹-GnRH-ethylamide (NEt)] received Food and Drug Administration approval in the United States. Others are marketed worldwide. Other analogs, both agonists and antagonists, will likely be available soon.